Evidence map›Paper›PMID 36628831›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2023

Airway bacterial community composition in persons with advanced cystic fibrosis lung disease.

Christina S Thornton, Lisa A Carmody, Linda M Kalikin, Kristopher Opron, Lindsay J Caverly, John J LiPuma

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Microbial and host innate immune factors affecting the persistence ofFrontiers in cellular and infection microbiology · 2026
    Review
  3. The cystic fibrosis pathogenJournal of medical microbiology · 2025
    Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christina S ThorntonDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Lisa A CarmodyDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Linda M KalikinDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Kristopher OpronDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Lindsay J CaverlyDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
John J LiPumaDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: jlipuma@med.umich.edu.
University of Michigan · US

Funding

Dynamics of airway microbiota at pulmonary exacerbation in cystic fibrosisR01HL136647 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIPUMA, JOHN J · 2017 to 2020
$1.3M
Omics of pulmonary exacerbations in cystic fibrosisR56HL126754 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIPUMA, JOHN J · 2016 to 2016
$388k
NHLBI NIH HHS R01 HL136647NHLBI NIH HHS R56 HL126754
6 · The paper itself

Abstract

backgroundThe progression of lung disease in people with cystic fibrosis (pwCF) has been associated with a decrease in the diversity of airway bacterial communities. How often low diversity communities occur in advanced CF lung disease and how they may be associated with clinical outcomes is not clear, however.

methodsWe sequenced a region of the bacterial 16S ribosomal RNA gene to characterize bacterial communities in sputum from 190 pwCF with advanced lung disease (FEV

resultsAlthough most of the 190 pwCF with advanced lung disease had airway bacterial communities characterized by low diversity with a dominant genus, a considerable minority (40%) did not. The absence of a dominant genus, presence of methicillin-susceptible Staphylococcus aureus, and greater bacterial richness positively correlated with lung function. Higher relative abundance of the dominant genus and greater antimicrobial use negatively correlated with lung function. PwCF with a low diversity community and dominant genus had reduced lung transplant-free survival compared to those without (median survival of 1.6 vs 2.9 years).

conclusionsA considerable proportion of pwCF with advanced lung disease do not have airway bacterial communities characterized by low diversity and a dominant genus and these individuals had better survival. An understanding of the antecedents of low diversity airway communities- and the impact these may have on lung disease trajectory - may provide avenues for improved management strategies.

Indexed as

Cystic FibrosisLung TransplantationMicrobiotaBacteriaHumansLungRNA, Ribosomal, 16SSputumRNA, Ribosomal, 16SBacterial community diversityCystic fibrosisMicrobiome

Identifiers

PMID36628831
OpenAlexW4313730540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.